Navigating the IRA: What Biopharmas Need to Know

Presented by BioCentury & Putnam


RECORDED: Thursday, March 30, 2023

The drug price-setting provisions of the Inflation Reduction Act (IRA) will reconfigure the commercial landscape in the U.S., forcing biopharma companies and their investors to develop new strategies for R&D and business success.

BioCentury, Putnam and a panel of industry experts discuss the Inflation Reduction Act and explain how the IRA will:

  • Impact your pipeline prioritization and portfolio investment strategies.
  • Affect when and whether you seek approvals for multiple indications.
  • Alter your business development and deal-making strategies.
  • Influence your orphan drug development strategies.
  • Change the calculation for venture investments in biotech.

Hosted By

BioCentury Logo
Putnam Logo